Nanoscope Therapeutics Announces Promising Results for MCO-010 Gene Therapy in Phase 2b RESTORE Trial

Nanoscope Therapeutics Inc. has announced positive top-line results from its Phase 2b RESTORE trial for MCO-010, a gene therapy for advanced retinitis pigmentosa (RP). The trial showed statistically significant improvements in best-corrected visual acuity (BCVA) at week 52 for both high and low doses compared to the control group. This marks a significant milestone as the trial is the first to demonstrate improvement beyond the clinically important BCVA threshold.

The effects of MCO-010 were durable, with visual function continuing to improve or remain stable up to week 76. The high-dose treatment group showed statistically significant improvement at week 76 compared to the control group. The results are consistent with previous findings from Phase 1/2a studies, with the high-dose MCO-010 planned for commercial use.